GLP1R and Parkinson disease: The GLP-1 analogue semaglutide showed multiple benefits in a MPTP-induced PD mouse model: it reduced the accumulation of α-synuclein, alleviated chronic inflammation, attenuated the peroxidation of lipid, inhibited the mitophagy related signaling and increased the expression of glial cell line-derived neurotrophic factor (GDNF).574 A clinical trial testing semaglutide in PD is ongoing.